Abstract:IntroductionElevated midkine (MK) expression may contribute to ventricular remodeling and ameliorate cardiac dysfunction after myocardial infarction (MI). Ex vivo modification of signaling mechanisms in mesenchymal stem cells (MSCs) with MK overexpression may improve the efficacy of cell-based therapy. This study sought to assess the safety and efficacy of MSCs with MK overexpression transplantation in a rat model of MI.MethodsA pLenO-DCE vector lentivirus encoding MK was constructed and infected in MSCs. MSC migration activity and cytoprotection was examined in hypoxia-induced H9C2 cells using transwell insert in vitro. Rats were randomized into five groups: sham, MI plus injection of phosphate buffered saline (PBS), MSCs, MSCs-green fluorescent protein (MSCs-GFP) and MSCs-MK, respectively. Survival rates were compared among groups using log-rank test and left ventricular function was measured by echocardiography at baseline, 4, 8 and 12 weeks.ResultsOverexpression of MK partially prevented hypoxia-induced MSC apoptosis and exerted MSC cytoprotection to anoxia induced H9C2 cells. The underlying mechanisms may be associated with the increased mRNA and protein levels of vascular endothelial growth factor (VEGF), transformation growth factor-β (TGF-β), insulin-like growth factor 1 (IGF-1) and stromal cell-derived factor 1 (SDF-1a) in MSCs-MK compared with isolated MSCs and MSCs-GFP. Consistent with the qPCR results, the culture supernatant of MSCs-MK had more SDF-1a (9.23 ng/ml), VEGF (8.34 ng/ml) and TGF-β1 (17.88 ng/ml) expression. In vivo, a greater proportion of cell survival was observed in the MSCs-MK group than in the MSCs-GFP group. Moreover, MSCs-MK administration was related to a significant improvement of cardiac function compared with other control groups at 12 weeks.ConclusionsTherapies employing MSCs with MK overexpression may represent an effective treatment for improving cardiac dysfunction and survival rate after MI.

Effect of Midkine, a Newly Heparin - Binding Cytokine, on Cardiovascular Functions

Promotion of Self-Renewal of Embryonic Stem Cells by Midkine

Multiple pathophysiological roles of midkine in human disease

Midkine: A multifaceted driver of atherosclerosis

Midkine Promotes Tetraspanin-Integrin Interaction and Induces Fak-Stat1 Alpha Pathway Contributing to Migration/Invasiveness of Human Head and Neck Squamous Cell Carcinoma Cells

Overexpression of Midkine Promotes the Viability of BA/F3 Cells.

Midkine Induces Epithelial-Mesenchymal Transition Through Notch2/Jak2-Stat3 Signaling in Human Keratinocytes

Mesenchymal stem cells with overexpression of midkine enhance cell survival and attenuate cardiac dysfunction in a rat model of myocardial infarction

Midkine and chronic kidney disease-associated multisystem organ dysfunctions

Ribozymes: the Hammerhead Swings into Action

Expression of Midkine in Eutopic and Ectopic Dndometrium of Patients with Adenomyosis after GnRHa Therapy

Targeting of midkine alleviates cardiac hypertrophy via attenuation of oxidative stress and autophagy

Midkine promotes renal fibrosis by stabilizing C/EBPβ to facilitate endothelial-mesenchymal transition

Midkine Upregulates Mica/B Expression in Human Gastric Cancer Cells and Decreases Natural Killer Cell Cytotoxicity

Human Urinary Kallidinogenase Pretreatment Inhibits Myocardial Inflammation and Apoptosis after Coronary Microembolization by Activating PI3K/Akt/FoxO1 Axis

Pharmacokinetics and Disposition of Heparin-Binding Growth Factor Midkine Antisense Oligonucleotide Nanoliposomes in Experimental Animal Species and Prediction of Human Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model

Midkine-Notch2 Pathway Mediates Excessive Proliferation of Airway Smooth Muscle Cells in Chronic Obstructive Lung Disease

Novel Functional Proteins Interact with Midkine in Hepatic Cancer Cells.

The effects of long term infusion tissue kallikrein and bradykinin on failing myocardium after myocardial infarction

Increased Midkine and Estrogen Receptor-Β Expression in Human Non-Small Cell Lung Cancer

Tissue Kallikrein and Kinin Infusion Rescues Failing Myocardium after Myocardial Infarction